Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDWAR:KRK 93 FCF Yield % is 4.95 as of Aug. 04, 2026, which is 35% below its 10-year median of 7.64. GuruFocus rates WAR:KRK with a GF Score™ of 93/100 and a GF Value™ of zł802.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Krka DD ranks better than 73.19% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Krka DD's Trailing 12-Month Free Cash Flow is zł1,710 Mil, and Market Cap is zł34,079 Mil. Therefore, Krka DD's FCF Yield % for today is 4.95%.
The historical rank and industry rank for Krka DD's FCF Yield % or its related term are showing as below:
WAR:KRK'
s FCF Yield % Range Over the Past 10 Years
Min: 2.2 Med: 7.64 Max: 13.53
Current: 4.95
During the past 13 years, the highest FCF Yield % of Krka DD was 13.53%. The lowest was 2.20%. And the median was 7.64%.
WAR:KRK's FCF Yield % is ranked better than 73.19% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.74
vs WAR:KRK: 4.95
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Krka DD FCF Yield % Related Terms
Krka DD FCF Yield % Historical Data
* Premium members only.
The historical data trend for Krka DD's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:KRK vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Krka DD's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (WAR:KRK) has a FCF Yield % of 4.95 as of Aug. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Krka DD and its competitors. This is 35% below median its historical median of 7.64. Over the past decade, Krka DD's FCF Yield % has ranged from 2.20 to 13.53. According to the industry distribution chart, Krka DD ranks #270 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Krka DD's FCF Yield % too high?
Krka DD's current FCF Yield % of 4.95 is 35% below median its 10-year median of 7.64. Over the past 10 years, this metric has ranged from a low of 2.20 to a high of 13.53. The Drug Manufacturers industry median FCF Yield % is 0.74. Krka DD's value of 4.95 is 568.9% above this industry median. Based on the distribution chart, Krka DD ranks #270 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #270 out of 1007 companies for FCF Yield %. This puts Krka DD in the upper half of its industry. The industry median FCF Yield % is 0.74. Krka DD's value of 4.95 is 568.9% above this benchmark. Historically, Krka DD's own FCF Yield % has ranged from 2.20 to 13.53 over the past decade. While the company's 10-year median is 7.64 vs. the industry median of 0.74, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.74, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current FCF Yield % of 4.95 is 568.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current FCF Yield % is 4.95, which is 35% below median its own 10-year median of 7.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (WAR:KRK) is currently considered Significantly Overvalued. The stock's GF Value™ is zł802.08, compared to a current price of zł1,130.00 — trading 40.9% above its estimated fair value. The current FCF Yield % is 4.95, which is 35% below median its 10-year median of 7.64 and 568.9% above the Drug Manufacturers industry median of 0.74. Krka DD's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Krka DD (WAR:KRK), the current FCF Yield % is 4.95 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (WAR:KRK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of zł1,130.00 is trading 40.9% above its estimated GF Value™ of zł802.08.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for WAR:KRK:
FCF Yield %: 4.95 (35% below median its 10-year median of 7.64)
GF Value™: zł802.08 vs. price of zł1,130.00 (40.9% above fair value)
Industry Position: 568.9% above the Drug Manufacturers median (#270 of 1007)
No single metric tells the full story. See the WAR:KRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
93GF Score
Get the complete analysis for WAR:KRK
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:KRK has been successfully added to your 
